A detailed history of Optas, LLC transactions in Astrazeneca PLC stock. As of the latest transaction made, Optas, LLC holds 15,570 shares of AZN stock, worth $984,491. This represents 0.28% of its overall portfolio holdings.

Number of Shares
15,570
Previous 5,693 173.49%
Holding current value
$984,491
Previous $443,000 173.81%
% of portfolio
0.28%
Previous 0.12%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$76.67 - $87.62 $757,269 - $865,422
9,877 Added 173.49%
15,570 $1.21 Million
Q2 2024

Jul 25, 2024

BUY
$66.81 - $80.83 $89,859 - $108,716
1,345 Added 30.93%
5,693 $443,000
Q1 2024

Apr 17, 2024

SELL
$61.03 - $69.57 $45,040 - $51,342
-738 Reduced 14.51%
4,348 $294,000
Q4 2023

Jan 25, 2024

BUY
$61.89 - $69.28 $25,870 - $28,959
418 Added 8.95%
5,086 $342,000
Q3 2023

Oct 31, 2023

BUY
$64.85 - $71.7 $34,111 - $37,714
526 Added 12.7%
4,668 $316,000
Q2 2023

Jul 20, 2023

BUY
$69.91 - $75.81 $22,161 - $24,031
317 Added 8.29%
4,142 $296,000
Q1 2023

Apr 17, 2023

SELL
$63.15 - $71.6 $13,893 - $15,751
-220 Reduced 5.44%
3,825 $265,000
Q4 2022

Jan 27, 2023

SELL
$54.21 - $70.44 $21,412 - $27,823
-395 Reduced 8.9%
4,045 $274,000
Q3 2022

Oct 31, 2022

BUY
$53.02 - $135.75 $46,233 - $118,374
872 Added 24.44%
4,440 $242,000
Q2 2022

Aug 01, 2022

BUY
$59.26 - $71.14 $28,207 - $33,862
476 Added 15.39%
3,568 $236,000
Q1 2022

Apr 26, 2022

SELL
$55.72 - $67.12 $18,443 - $22,216
-331 Reduced 9.67%
3,092 $205,000
Q4 2021

Jan 26, 2022

BUY
$54.02 - $63.83 $184,910 - $218,490
3,423 New
3,423 $200,000
Q4 2020

Jan 27, 2021

SELL
$48.52 - $58.02 $242,939 - $290,506
-5,007 Closed
0 $0
Q3 2020

Oct 23, 2020

BUY
$53.07 - $61.1 $265,721 - $305,927
5,007 New
5,007 $275,000

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $196B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Optas, LLC Portfolio

Follow Optas, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Optas, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Optas, LLC with notifications on news.